⚠ Evidence warning: Clinical trials or other evidence do not support the claims that a low-oxalate diet and low-dose naltrexone relieve vulvodynia. This page keeps it as a report of what people, websites or other media say.
Vulvodynia
Table of Contents
- Overview and Definition
- Classification: Provoked vs Generalized
- Causes and Contributing Factors
- Symptoms
- Diagnosis
- Pelvic Floor Dysfunction
- Topical and Local Treatments
- Systemic Treatments
- Low-Oxalate Diet and Lifestyle
- Vestibulectomy
- Psychosexual Impact and Support
- Prognosis
- Non-Drug Options Studied in Recent Trials
- Key Research Papers
- Connections
- Featured Videos
Overview and Definition
Vulvodynia is a chronic vulvar pain disorder lasting at least 3 months, without an identifiable cause on examination or laboratory testing that would fully explain it. It is defined by the International Society for the Study of Vulvovaginal Disease (ISSVD) as vulvar pain of at least 3 months' duration, in the absence of relevant visible findings or a specific, clinically identifiable neurological disorder.
Vulvodynia affects an estimated 8–16% of women at some point in their lives, making it one of the most common causes of vulvar pain — yet it remains profoundly underdiagnosed and undertreated. In a Boston population study, nearly 40% of women with chronic vulvar pain chose not to seek treatment, and of those who did, 60% saw 3 or more doctors, many of whom could not provide a diagnosis. In a Michigan population study, 48.6% of the women meeting the criteria had sought treatment and only 1.4% had been diagnosed with vulvodynia. Many women report being told that "nothing is wrong" or that the pain is psychological. Vulvodynia is a real, physical condition with identifiable neurobiological, musculoskeletal, and hormonal contributors.
The name derives from the Latin vulva and Greek odyne (pain). Historical terms including "vulvodynia" (as a catch-all), "vulvar vestibulitis syndrome," and "essential vulvodynia" have been standardized by the ISSVD into a classification by site (localized vs. generalized) and provocation (provoked vs. spontaneous vs. mixed).
Classification: Provoked vs Generalized
The ISSVD 2015 classification organizes vulvodynia along two axes: anatomical site and stimulus relationship.
By Anatomical Site
- Localized vulvodynia — pain confined to a specific area: most commonly the vestibule (the tissue surrounding the vaginal opening), also the clitoris (clitorodynia), or the left or right hemivulva
- Generalized vulvodynia — pain distributed across the entire vulva without a clear focal point
By Stimulus Relationship
- Provoked vulvodynia / vestibulodynia — pain that occurs only in response to physical contact or pressure (touch, intercourse, tampon insertion, bicycle riding, prolonged sitting, tight clothing). By far the most common subtype, affecting 90% of women diagnosed with vulvodynia. The vestibule is almost always the primary pain site. Also called provoked vestibulodynia (PVD), formerly "vulvar vestibulitis syndrome."
- Spontaneous vulvodynia — constant or near-constant burning, stinging, or aching pain without a triggering touch. More common in older women and in the context of generalized distribution.
- Mixed vulvodynia — components of both provoked and spontaneous pain.
Primary vs Secondary PVD
- Primary PVD — pain present from the first attempted intercourse or tampon use; the patient has never been pain-free with penetration
- Secondary PVD — pain developed after a period of pain-free sexual activity; more commonly linked to hormonal changes (oral contraceptive use, postpartum estrogen drop), recurrent yeast infections, or triggering events
Causes and Contributing Factors
Vulvodynia is almost certainly multifactorial, with different contributors playing different roles in different women. No single cause has been established, and the disorder is best understood as a central and peripheral pain sensitization syndrome with several entry points.
Neuroproliferative / Peripheral Sensitization
- Women with PVD have a significantly higher density of sensory nerve fibers (particularly C-fibers expressing substance P and calcitonin gene-related peptide (CGRP)) in the vestibular epithelium compared to controls — a form of neuroproliferation driven by chronic mast cell activation and local inflammatory cytokines
- Lowered pain thresholds (allodynia — pain from normally non-painful stimuli; hyperalgesia — amplified pain from painful stimuli) reflect peripheral sensitization of these excess nerve fibers
Hormonal Factors
- Combined oral contraceptives (COCs) — reduce free testosterone and increase sex hormone-binding globulin (SHBG), described as causing vestibular atrophy, reduced lubrication, and increased sensitivity; starting COCs in adolescence (before the vulva has fully matured hormonally) has been reported as a risk factor for secondary PVD. The link is disputed. A Quebec case-control study (138 women with the condition, 309 controls) found a relative risk of 6.6 for ever-users and 9.3 for first use before age 16, higher with pills of high progestogenic, high androgenic and low estrogenic potency. Population-based studies found less: a Michigan study of 906 women found no association (hazard ratio 1.08), and a Boston study found a nonsignificant 30% increase overall, with an odds ratio of 2.5 for first use before age 18
- Postpartum estrogen deficiency — breastfeeding suppresses estrogen to near-menopausal levels; vulvar atrophy and provoked pain after delivery are common
- Perimenopause and menopause — genitourinary syndrome of menopause (GSM) causes vulvar atrophy, loss of elasticity, and increased pain with contact; distinguishing GSM from vulvodynia requires careful examination
Pelvic Floor Dysfunction
- Hypertonic (overactive) pelvic floor muscles — a near-universal finding in PVD; the chronic guarding response to anticipated pain creates a vicious cycle: pain triggers muscle bracing, bracing causes pain
- Trigger points in the levator ani, obturator internus, and piriformis muscles refer pain to the vestibule and perineum
Genetic and Immune Factors
- Polymorphisms in the interleukin-1 (IL-1) receptor antagonist gene increase local inflammatory response to Candida and other vaginal pathogens, predisposing to vestibular inflammation and nerve sensitization
- Altered Toll-like receptor 2 and Toll-like receptor 4 expression in vestibular fibroblasts from women with PVD suggests an exaggerated innate immune response to commensal organisms
Recurrent Candidal Vulvovaginitis
- Repeated yeast infections — particularly with prolonged antifungal treatment — can trigger and perpetuate vestibular nerve sensitization; many women date the onset of PVD to a first or recurrent yeast infection
Central Sensitization
- Many women with vulvodynia have comorbid conditions characteristic of central sensitization: fibromyalgia, interstitial cystitis/painful bladder syndrome, temporomandibular disorders, irritable bowel syndrome, chronic headaches
- Functional magnetic resonance imaging (fMRI) studies show altered pain processing in brain regions including the insula and anterior cingulate cortex
Symptoms
- Burning — the most characteristic description; often described as a raw, stinging, or scalded sensation
- Stinging or cutting pain — particularly with penetration or touch
- Rawness — feeling as though the skin has been abraded or scraped
- Provoked pain — dyspareunia (painful intercourse), pain with tampon insertion, gynecological exams, bike riding, tight-waistband clothing, prolonged sitting
- Aching or throbbing — may persist for hours or days after provocation in PVD; the hallmark "after-burn"
- Itching — less common; usually secondary to neurogenic itch rather than infection
- Secondary vaginismus — involuntary contraction of pelvic floor muscles in anticipation of painful penetration; may develop after months or years of painful intercourse
Diagnosis
Vulvodynia is a diagnosis of exclusion: identifiable causes of vulvar pain are ruled out before the diagnosis is made. The clinical workup includes:
History
- Duration, location, quality, and triggers of pain
- Relationship to menstrual cycle, hormonal medications, pregnancy
- Sexual history including onset of pain in relation to first intercourse
- Gynecological history: yeast infections, sexually transmitted infections (STIs), prior vulvar biopsies or surgeries
- Comorbid conditions: interstitial cystitis, irritable bowel syndrome (IBS), fibromyalgia, anxiety, depression
Physical Examination
- External inspection — normally unremarkable in vulvodynia; erythema of the vestibule may be present but is non-specific
- Cotton-swab test — light touch with a cotton-tipped swab applied to the posterior vestibule (5 and 7 o'clock positions) and the labia minora; a pain score of 5–10 out of 10 on vestibular touch with no or minimal pain elsewhere is the hallmark finding of PVD; the test maps the pain distribution
- Pelvic floor assessment — external and internal palpation of levator ani, obturator internus, and piriformis for hypertonicity and trigger points
- Speculum exam — if tolerated; assesses for vulvar skin changes (lichen sclerosus, lichen planus), atrophy, or discharge
Laboratory Testing
- Vaginal pH and wet prep — to exclude bacterial vaginosis and Trichomonas
- Vaginal culture for Candida (speciation matters — Candida glabrata responds differently to azoles than C. albicans)
- Sexually transmitted infection testing (chlamydia, gonorrhea) as appropriate
- Hormone levels (follicle-stimulating hormone (FSH), estradiol, total and free testosterone) in women on hormonal contraceptives or with atrophic changes
Conditions to Exclude
- Lichen sclerosus, lichen planus, contact dermatitis, psoriasis (skin biopsy if indicated)
- Active candidal or bacterial vaginosis infection
- Genitourinary syndrome of menopause (atrophic vaginitis)
- Pudendal neuralgia (differentiated by positional component — worse sitting, relieved standing; extends to perineum and rectum)
- Vulvar intraepithelial neoplasia (VIN) — suspicious lesions are biopsied
Pelvic Floor Dysfunction
Pelvic floor physical therapy (PT) is the single most evidence-backed first-line treatment for PVD, with a 50–80% response rate in randomized and observational studies. The hypertonic pelvic floor found in most women with PVD is both a consequence of chronic pain and a perpetuating cause — making PT essential regardless of which other treatments are used.
A multicenter head-to-head trial enrolled 212 women in Canada and compared 10 weeks of weekly multimodal physical therapy (education, pelvic floor exercises with biofeedback, manual therapy and dilation) with overnight 5% lidocaine ointment. Pain during intercourse ended 1.8 points lower on a 0–10 scale with physical therapy, and the difference held at 6 months. At the end of treatment, 79% of the physical therapy group felt very much or much improved, compared with 39% of the lidocaine group. The trial had no placebo group.
- What pelvic PT involves: external and (with consent) internal manual therapy of the pelvic floor muscles, connective tissue mobilization, myofascial release, trigger point pressure, biofeedback, and home exercises including paradoxical relaxation (learning to release rather than contract the pelvic floor)
- Biofeedback — surface electromyography (sEMG) or manometry provides real-time visual feedback on pelvic floor muscle tension; patients learn to identify and reduce involuntary baseline hypertonicity; particularly effective when combined with manual therapy
- Dilators — graduated vaginal dilators used at home promote progressive desensitization and pelvic floor relaxation; typically introduced after the pelvic floor is partially relaxed through manual therapy
- Botulinum toxin injections — for refractory pelvic floor hypertonicity; injected into the bulbocavernosus and pubococcygeus muscles under EMG guidance; randomized data are mixed. A 2025 pooled analysis of 4 randomized trials (244 women) found no significant pain reduction compared with placebo; a trial of 88 women found no significant reduction in its main measure of intercourse or tampon pain, though weekly tampon pain, a secondary measure, did fall; a trial of 64 women found no difference at 6 months; and a trial of 60 women using muscle-signal (electromyography) guidance reported lower pain at 3 months (5.04 compared with 7.37 on placebo); duration of effect 3–6 months; repeat injections are often required
- Finding a pelvic PT — the American Physical Therapy Association's Academy of Pelvic Health directory and the National Vulvodynia Association referral list are the most reliable resources in the US; an ideal therapist has specific postgraduate training in pelvic floor disorders and experience with vulvodynia
Topical and Local Treatments
- Topical lidocaine — 2% lidocaine gel or 5% ointment applied to the vestibule 30 minutes before intercourse and up to 4 times daily; reduces provoked pain acutely; in an uncontrolled study of 61 women using 5% lidocaine ointment nightly for a mean of 7 weeks, 76% could have intercourse afterwards, compared with 36% before, and the authors called for a randomized trial. The later randomized, placebo-controlled trial (133 women, 12 weeks) found that lidocaine cream did not reduce tampon-test pain more than placebo (20% reduction compared with 33%)
- Topical estrogen or estrogen-testosterone cream — particularly effective in secondary PVD associated with hormonal contraceptive use or postpartum/perimenopausal estrogen deficiency; applied directly to the vestibule nightly; restores vestibular tissue trophicity; often combined with discontinuing the offending combined oral contraceptive
- Topical testosterone — 2% testosterone propionate in petroleum jelly applied to the vestibule; increases vestibular androgen receptor stimulation; some evidence for benefit when combined with topical estrogen in OCP-associated PVD
- Topical cromolyn sodium — mast cell stabilizer; described as reducing mast cell degranulation and local neurogenic inflammation in the vestibule; available compounded at 4%. In the one placebo-controlled trial found (26 evaluable patients), 4% cromolyn cream did not give a significant benefit: 38% on cromolyn and 46% on placebo felt their symptoms fell by half or more
- Capsaicin — depletes substance P from C-fibers; 0.025% applied to the vulva nightly in small studies showed benefit but is poorly tolerated due to initial burning; not widely used
- Compounded baclofen + diazepam suppositories — vaginal or rectal use; relaxes internal pelvic floor smooth and striated muscle; most useful as adjunct to pelvic PT for hypertonic pelvic floor. The diazepam half has one placebo-controlled trial: 10 mg vaginal suppositories nightly for 4 weeks in 21 women with tight pelvic floor muscles (not limited to vulvodynia) showed no difference from placebo in muscle tension or in symptom questionnaires
Systemic Treatments
- Tricyclic antidepressants (TCAs) — amitriptyline and nortriptyline (10–150 mg nightly) reduce neuropathic pain by inhibiting sodium channels and norepinephrine-serotonin reuptake; sedating side effects make nighttime dosing practical; nortriptyline is better tolerated than amitriptyline
- Serotonin-norepinephrine reuptake inhibitors (duloxetine, venlafaxine) — comparable neuropathic pain mechanism to tricyclic antidepressants; duloxetine 30–120 mg daily; often better tolerated than tricyclic antidepressants in terms of anticholinergic burden; preferred when comorbid depression or fibromyalgia is present
- Gabapentinoids (gabapentin, pregabalin) — reduce central sensitization by inhibiting voltage-gated calcium channels; gabapentin 300–3600 mg/day in divided doses; topical gabapentin 6% (compounded) applied locally is an alternative to reduce systemic side effects (dizziness, weight gain, cognitive fog)
- Oral contraceptive discontinuation — in women who developed PVD on COCs, stopping the pill and transitioning to non-hormonal contraception or a progestin-only method (a levonorgestrel intrauterine device) with local estrogen supplementation resolves or significantly improves symptoms in a meaningful subset; SHBG levels normalize over 3–6 months
- Low-dose naltrexone — 1.5–4.5 mg nightly; emerging evidence for central sensitization conditions including vulvodynia; reduces neuroinflammation via Toll-like receptor 4 modulation; not yet first-line but increasingly used off-label
- Antihistamines — hydroxyzine 25–75 mg at bedtime; reduces mast cell-mediated vestibular inflammation; particularly useful when itching or burning is associated with histamine-type reactions or when symptoms worsen with foods high in histamine
Two of the common pills have been tested against placebo with negative results. Extended-release gabapentin (1,200–3,000 mg/day) was no better than placebo for tampon-test pain in a crossover trial of 89 women (4.0 compared with 4.3 on a 0–10 scale). Desipramine, a tricyclic antidepressant, was no better than placebo in a 133-woman trial (24% compared with 33% pain reduction). A 2026 network meta-analysis concluded that commonly prescribed drugs "lack robust evidence of superiority over placebo." Placebo alone gave a 33% pain reduction in that desipramine trial, and its authors put the improvement seen in every group down to placebo or placebo-independent effects, so a success rate from a study with no comparison group can reflect those effects as well.
Low-Oxalate Diet and Lifestyle
The low-oxalate diet for vulvodynia is based on the hypothesis that urinary oxalate crystals irritate the vestibular tissue, contributing to pain. While the mechanism remains debated and evidence is observational rather than from randomized trials, many women report symptom relief. The diet is nutritionally safe when managed carefully.
- High-oxalate foods the diet limits: spinach, beets, Swiss chard, rhubarb, unfermented soy products, nuts and nut butters (especially almonds and peanuts), wheat bran, black tea, dark chocolate, sweet potatoes, and most berries
- Low-oxalate alternatives: kale, cauliflower, broccoli, cabbage, peas, mushrooms, green beans, brown rice, pasta, poultry, fish, eggs, dairy (calcium binds oxalate in the gut and reduces absorption)
- Calcium citrate supplementation — 200–400 mg with meals; calcium citrate binds dietary oxalate in the gut before absorption, reducing urinary oxalate; calcium carbonate also lowered urinary oxalate excretion (by 41.2%) in a small crossover study of 17 people with chronic kidney disease; some practitioners recommend calcium as primary intervention over strict dietary restriction
- Hydration — adequate fluid intake (at least 2 liters daily) dilutes urinary oxalate concentration
- Vulvar hygiene — the usual practitioner list leaves out perfumed soaps, bubble baths and detergents with optical brighteners; uses unscented glycerin-free soap or plain water for vulvar cleansing; favors breathable cotton underwear; and leaves out pantiliners with synthetic fibers (practitioners apply the same irritation reasoning here)
- Lubricants — silicone-based lubricants are often preferred over water-based (which often contain glycerin or propylene glycol, potential irritants); flavoring, warming agents and antimicrobials in a lubricant are described as further irritants
Vestibulectomy
Vestibulectomy — specifically modified posterior vestibulectomy with vaginal advancement — is a surgical procedure that removes the hypersensitive, nerve-dense vestibular tissue and advances the vaginal mucosa to cover the defect. It is indicated for localized PVD that has failed conservative management (pelvic PT, topical/systemic medications) for at least 6 months.
- Who is a candidate: women with well-localized PVD (positive cotton-swab test focused on the posterior vestibule), whose pain is predominantly provoked (not spontaneous), who have completed adequate trials of pelvic PT and topical therapy, and who have no active infection or untreated pelvic floor hypertonicity
- Procedure: under general or regional anesthesia, the affected vestibular tissue (typically the posterior vestibule from 3 to 9 o'clock, including the hymeneal ring) is excised; the vaginal mucosa is advanced and sutured to the perineal skin; minor superficial glands may be removed; the procedure takes 30–60 minutes
- Outcomes: the most effective treatment for refractory PVD with success rates of 60–90% in carefully selected patients; a 2001 randomized controlled trial of 78 women found vestibulectomy significantly more successful than biofeedback and group cognitive-behavioral therapy at 6 months, though its authors say this "needs to be interpreted with caution" because seven women assigned to surgery did not go ahead with it. A 2024 retrospective study from one surgeon (80 patients with complete data, median follow-up 21 months) reported pain scores down 65–80% on cotton-swab testing, 75% needing no further treatment, and limited wound separation in 22.6%; it had no comparison group
- Recovery: 4–6 weeks of pelvic rest; graduated dilator use begins at 6 weeks; pelvic PT commonly runs alongside recovery to address any residual pelvic floor hypertonicity; full recovery and return to pain-free intercourse typically takes 3–6 months
- Risks: infection, hematoma, scarring, change in perineal appearance, rare worsening of pain (especially when pelvic floor hypertonicity is not addressed), altered sensation (usually temporary)
- Prerequisite: pelvic floor hypertonicity is treated concurrently or pre-operatively — surgeons describe vestibulectomy as failing when severe pelvic floor muscle dysfunction persists
Psychosexual Impact and Support
Vulvodynia profoundly affects sexuality, relationships, and mental health. The psychosexual impact is not a cause of vulvodynia but an important comorbidity that, if unaddressed, perpetuates the pain cycle.
- Depression and anxiety — affect approximately 40–60% of women with vulvodynia; pain-related mood disturbance is independent of whether pain is the primary cause or effect; the two are usually treated together
- Relationship strain — avoidance of sexual activity due to pain strains intimacy and communication; partners may misinterpret pain-driven avoidance as rejection; couples counseling significantly improves outcomes in randomized studies. In a trial of 108 women and their partners, cognitive-behavioral couple therapy beat lidocaine on pain unpleasantness at 6 months, and on pain anxiety, catastrophizing (expecting the worst from pain) and treatment satisfaction after treatment and at 6 months
- Fear-avoidance model — anticipation of pain leads to anxiety, hypervigilance, and muscle bracing before touch occurs; the brain encodes pain responses that then fire before physical contact; cognitive-behavioral therapy (CBT) specifically targeting pain catastrophizing and fear-avoidance is a validated psychological intervention for vulvodynia
- Mindfulness-based therapy — mindfulness for vulvodynia programs (8-week protocols adapted from mindfulness-based stress reduction) reduce pain intensity, sexual distress, and catastrophizing in randomized trials; improve central pain modulation. Among 130 women given 8 weeks of group mindfulness-based or group cognitive-behavioral therapy, gains in pain and sex-related distress held at 12 months, with no difference between the two
- Sex therapy — with a certified sex therapist familiar with vulvodynia; focuses on graduated sensate focus exercises, non-penetrative intimacy, communication skills, and reframing sexuality outside penetration
- Online communities and peer support — the National Vulvodynia Association (NVA) and online forums provide community for a condition marked by isolation and medical dismissal; validated peer support is protective against depression
Prognosis
Vulvodynia is a treatable condition — not a life sentence of pain. Prognosis is strongly related to access to informed, multidisciplinary care.
- Approximately 50–70% of women with PVD achieve significant or complete pain resolution with multimodal treatment (pelvic PT + topical treatment + psychological support); vestibulectomy raises this to 60–90% in the surgical subgroup
- A longitudinal population-based study (Reed et al., 2016) followed 239 women who screened positive: 50.6% remitted without relapse, 39.7% relapsed after remission and 9.6% stayed positive throughout, with about half of those who remitted relapsing within 6–30 months — suggesting that natural history includes significant spontaneous improvement, though waiting without treatment prolongs suffering
- Women who receive care from specialists familiar with vulvodynia (urogynecologists, vulvologists, experienced pelvic PTs, sex therapists) have meaningfully better outcomes than those receiving only primary care
- Comorbid central sensitization conditions (fibromyalgia, interstitial cystitis, irritable bowel syndrome) require concurrent management and may limit response to local vulvar treatments alone; systemic neuropathic pain agents are more likely to be needed in this subgroup
- The prognostic message specialists give patients: this is real, it is physical, effective treatments exist, and many women improve as they keep moving through the treatment ladder
Non-Drug Options Studied in Recent Trials
A 2024 meta-analysis of 9 randomized trials (332 patients) found that rehabilitation treatments lowered pain during intercourse more than placebo, sham treatment or a waiting list, with significant effects for acupuncture and for shockwave therapy. Its authors call for further evidence.
A 2026 network meta-analysis compared treatments across 33 studies and 1,873 women. "Tissue-based" treatments (low-level laser and other light therapy, nerve stimulation through the vagina, and shockwave therapy) were the only group clearly better than placebo, with moderate confidence, right after treatment and again at 3–6 months. Compared with no treatment at all, physical therapy, acupuncture and psychological approaches also reduced pain, with low to moderate confidence.
Key Research Papers
- Bornstein J, Goldstein AT, Stockdale CK, et al. 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. Obstetrics & Gynecology. 2016;127(4):745–751. — PubMed PMID: 27008217 · doi:10.1097/aog.0000000000001359
- Reed BD, Harlow SD, Sen A, Legocki LJ, Edwards RM, Arato N, Haefner HK. Prevalence and Demographic Characteristics of Vulvodynia in a Population-Based Sample. American Journal of Obstetrics & Gynecology. 2012;206(2):170.e1–9. — PubMed PMID: 21963307 · doi:10.1016/j.ajog.2011.08.012
- Harlow BL, Stewart EG. A Population-Based Assessment of Chronic Unexplained Vulvar Pain: Have We Underestimated the Prevalence of Vulvodynia? Journal of the American Medical Women's Association. 2003;58(2):82–88. — PubMed PMID: 12744420
- Goldstein AT, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: Assessment and Treatment. Journal of Sexual Medicine. 2016;13(4):572–590. — PubMed PMID: 27045258 · doi:10.1016/j.jsxm.2016.01.020
- Bergeron S, Binik YM, Khalife S, et al. A Randomized Comparison of Group Cognitive-Behavioral Therapy, Surface Electromyographic Biofeedback, and Vestibulectomy in the Treatment of Dyspareunia Resulting from Vulvar Vestibulitis. Pain. 2001;91(3):297–306. — PubMed PMID: 11275387 · doi:10.1016/s0304-3959(00)00449-8
- Pukall CF, Goldstein AT, Bergeron S, et al. Vulvodynia: Definition, Prevalence, Impact, and Pathophysiological Factors. Journal of Sexual Medicine. 2016;13(3):291–304. — PubMed PMID: 26944461 · doi:10.1016/j.jsxm.2015.12.021
- Goldstein AT, Belkin ZR, Krapf JM, et al. Polymorphisms of the Androgen Receptor Gene and Hormonal Contraceptive Induced Provoked Vestibulodynia. Journal of Sexual Medicine. 2014;11(11):2764–2771. — PubMed PMID: 25187224 · doi:10.1111/jsm.12668
- Landry T, Bergeron S, Dupuis MJ, Desrochers G. The Treatment of Provoked Vestibulodynia: A Critical Review. Clinical Journal of Pain. 2008;24(2):155–171. — PubMed PMID: 18209522 · doi:10.1097/ajp.0b013e31815aac4d
- Haefner HK, Collins ME, Davis GD, et al. The Vulvodynia Guideline. Journal of Lower Genital Tract Disease. 2005;9(1):40–51. — PubMed PMID: 15870521 · doi:10.1097/00128360-200501000-00009
- Bohm-Starke N, Hilliges M, Falconer C, Rylander E. Increased Intraepithelial Innervation in Women with Vulvar Vestibulitis Syndrome. Gynecologic and Obstetric Investigation. 1998;46(4):256–260. — PubMed PMID: 9813445 · doi:10.1159/000010045
- ter Kuile MM, van Lankveld JJ, de Groot E, Melles R, Neffs J, Zandbergen M. Cognitive-Behavioral Therapy for Women with Lifelong Vaginismus: Process and Prognostic Factors. Behaviour Research and Therapy. 2007;45(2):359–373. — PubMed PMID: 16701078 · doi:10.1016/j.brat.2006.03.013
- Brauer M, ter Kuile MM, Laan E. Effects of Appraisal of Sexual Stimuli on Sexual Arousal in Women with and without Superficial Dyspareunia. Archives of Sexual Behavior. 2009;38(4):476–485. — PubMed PMID: 18561015 · doi:10.1007/s10508-008-9371-8
- Zolnoun DA, Hartmann KE, Steege JF. Overnight 5% Lidocaine Ointment for Treatment of Vulvar Vestibulitis. Obstetrics & Gynecology. 2003;102(1):84–87. — PubMed PMID: 12850611 · doi:10.1016/s0029-7844(03)00368-5
- Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, Poleshuck EL, Stodgell CJ, Dworkin RH. Oral Desipramine and Topical Lidocaine for Vulvodynia: A Randomized Controlled Trial. Obstetrics & Gynecology. 2010;116(3):583–593. — PubMed PMID: 20733439 · doi:10.1097/AOG.0b013e3181e9e0ab
- Brown CS, Bachmann GA, Wan J, Foster DC; Gabapentin (GABA) Study Group. Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial. Obstetrics & Gynecology. 2018;131(6):1000–1007. — PubMed PMID: 29742655 · doi:10.1097/AOG.0000000000002617
- Morin M, Dumoulin C, Bergeron S, Mayrand MH, Khalifé S, Waddell G, Dubois MF; PVD Study Group. Multimodal Physical Therapy Versus Topical Lidocaine for Provoked Vestibulodynia: A Multicenter, Randomized Trial. American Journal of Obstetrics & Gynecology. 2021;224(2):189.e1–189.e12. — PubMed PMID: 32818475 · doi:10.1016/j.ajog.2020.08.038
- Spinillo A, Dominoni M, Tiranini L, Cassani C, Nappi RE, Gardella B. Beyond the Placebo Effect: A Systematic Review and a Network Meta-Analysis of Treatment Strategies for Vulvodynia. BMC Women's Health. 2026;26(1):249. — PubMed PMID: 41975391 · doi:10.1186/s12905-026-04469-0
- Calafiore D, Marotta N, Curci C, Agostini F, De Socio RI, Inzitari MT, Ferraro F, Bernetti A, Ammendolia A, de Sire A. Efficacy of Rehabilitative Techniques on Pain Relief in Patients With Vulvodynia: A Systematic Review and Meta-Analysis. Physical Therapy. 2024;104(7):pzae054. — PubMed PMID: 38564267 · doi:10.1093/ptj/pzae054
- Gao Z, Hu L, Yi C, Gao C. Clinical Impacts of Botulinum Toxin Type A Injections for Provoked Vestibulodynia: Insights From Randomized Controlled Trials. BMC Women's Health. 2025;25(1):590. — PubMed PMID: 41339844 · doi:10.1186/s12905-025-04156-6
- Haraldson P, Mühlrad H, Heddini U, Nilsson K, Bohm-Starke N. Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial. Obstetrics & Gynecology. 2020;136(3):524–532. — PubMed PMID: 32769643 · doi:10.1097/AOG.0000000000004008
- Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum Toxin Type A-a Novel Treatment for Provoked Vestibulodynia? Results From a Randomized, Placebo Controlled, Double Blinded Study. Journal of Sexual Medicine. 2009;6(9):2523–2537. — PubMed PMID: 19619148 · doi:10.1111/j.1743-6109.2009.01378.x
- Pelletier F, Gallais Sérézal I, Puyraveau M, Leroux F, Verollet D, Aubin F, Amarenco G, Parratte B. Electromyography-Guided Botulinum Toxin Injections in Provoked Vestibulodynia: A Randomized Double-Blind Placebo-Controlled Clinical Trial. American Journal of Obstetrics & Gynecology. 2026;234(5):1362–1369. — PubMed PMID: 41419152 · doi:10.1016/j.ajog.2025.12.037
- Reed BD, Harlow SD, Plegue MA, Sen A. Remission, Relapse, and Persistence of Vulvodynia: A Longitudinal Population-Based Study. Journal of Women's Health. 2016;25(3):276–283. — PubMed PMID: 26752153 · doi:10.1089/jwh.2015.5397
- Bouchard C, Brisson J, Fortier M, Morin C, Blanchette C. Use of Oral Contraceptive Pills and Vulvar Vestibulitis: A Case-Control Study. American Journal of Epidemiology. 2002;156(3):254–261. — PubMed PMID: 12142260 · doi:10.1093/aje/kwf037
- Reed BD, Harlow SD, Legocki LJ, Helmuth ME, Haefner HK, Gillespie BW, Sen A. Oral Contraceptive Use and Risk of Vulvodynia: A Population-Based Longitudinal Study. BJOG. 2013;120(13):1678–1684. — PubMed PMID: 23937077 · doi:10.1111/1471-0528.12407
- Harlow BL, Vitonis AF, Stewart EG. Influence of Oral Contraceptive Use on the Risk of Adult-Onset Vulvodynia. Journal of Reproductive Medicine. 2008;53(2):102–110. — PubMed PMID: 18357801
- Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Small MJ, Gelone SP. Cromolyn Cream for Recalcitrant Idiopathic Vulvar Vestibulitis: Results of a Placebo Controlled Study. Sexually Transmitted Infections. 2001;77(1):53–57. — PubMed PMID: 11158692 · doi:10.1136/sti.77.1.53
- Crisp CC, Vaccaro CM, Estanol MV, Oakley SH, Kleeman SD, Fellner AN, Pauls RN. Intra-Vaginal Diazepam for High-Tone Pelvic Floor Dysfunction: A Randomized Placebo-Controlled Trial. International Urogynecology Journal. 2013;24(11):1915–1923. — PubMed PMID: 23681047 · doi:10.1007/s00192-013-2108-9
- Caravaca F, Ruiz AB, Escola JM, Hernández Gallego R, Cerezo I, Fernández N, Barroso S, Martín MV. Either Calcium Carbonate or Sevelamer Decreases Urinary Oxalate Excretion in Chronic Renal Failure Patients [in Spanish]. Nefrología. 2007;27(4):466–471. — PubMed PMID: 17944584
- Coryn N, Vergauwe B, Weyers S, Verstraelen H. Long-Term Effectiveness of Vestibulectomy for the Treatment of Vulvodynia: A Retrospective Cohort Study. Journal of Lower Genital Tract Disease. 2024;28(3):258–263. — PubMed PMID: 38864720 · doi:10.1097/LGT.0000000000000810
- Bergeron S, Vaillancourt-Morel MP, Corsini-Munt S, Steben M, Delisle I, Mayrand MH, Rosen NO. Cognitive-Behavioral Couple Therapy Versus Lidocaine for Provoked Vestibulodynia: A Randomized Clinical Trial. Journal of Consulting and Clinical Psychology. 2021;89(4):316–326. — PubMed PMID: 34014693 · doi:10.1037/ccp0000631
- Brotto LA, Bergeron S, Zdaniuk B, Basson R. Mindfulness and Cognitive Behavior Therapy for Provoked Vestibulodynia: Mediators of Treatment Outcome and Long-Term Effects. Journal of Consulting and Clinical Psychology. 2020;88(1):48–64. — PubMed PMID: 31841023 · doi:10.1037/ccp0000473
PubMed Topic Searches
- PubMed: Vulvodynia
- PubMed: Provoked vestibulodynia
- PubMed: Vulvar vestibulitis syndrome
- PubMed: Vulvodynia pelvic floor therapy
- PubMed: Vestibulectomy dyspareunia
- PubMed: Low oxalate diet vulvodynia
- PubMed: Vulvodynia tricyclic antidepressants
- PubMed: Pelvic floor dysfunction dyspareunia
- PubMed: Vulvodynia oral contraceptive
- PubMed: Vulvar pain central sensitization
Connections
- Reproductive Medicine
- Bacterial Vaginosis
- Endometriosis
- Infertility
- Ectopic Pregnancy
- Menopause and Hormone Replacement Therapy
- Ovarian Cysts
- PMS and PMDD
- Preeclampsia
- Uterine Fibroids
- Yeast Infections
- Pelvic Inflammatory Disease
- Chronic Pain
- Irritable Bowel Syndrome
- Interstitial Cystitis
- Vitamin D3